Coty Inc header image

Coty Inc

COTY

Equity

ISIN null / Valor 1645885

New York Stock Exchange, Inc (2026-06-05)
USD 1.96+5.95%

Coty Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Coty Inc. is a global beauty company with a history that spans over a century, marking its significance in transforming the beauty industry into what it is today. The company boasts a diverse portfolio of over 50 iconic cosmetic, skincare, and fragrance brands. Coty's business strategy is rooted in innovation and excellence, aiming to empower and enable all visions of beauty through its products. The company emphasizes the importance of science and passion as key drivers behind its mission to offer new, innovative, and science-based beauty solutions. Coty Inc. positions itself as a forward-thinking entity in the beauty sector, dedicated to supporting diverse and evolving concepts of beauty that resonate with individuals on a personal level.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (13.05.2026):

Coty Inc. reported results for the third quarter of fiscal 2026 (quarter ended March 31, 2026). Revenue was essentially stable on a reported basis but softer on a like‑for‑like basis, the company delivered profit results ahead of expectations after cost control and investment reallocation, and management implemented the Coty.Curated strategic framework while taking a large non‑cash impairment in the Consumer Beauty business that drove a reported operating loss. Key adjusted and cash metrics were weaker year‑over‑year but FY‑to‑date cash generation improved.

Headline financials

Q3 net revenue $1,281.6M (‑1% reported, ‑7% LFL). Reported operating loss $372.0M driven largely by a $362.8M impairment in Consumer Beauty; adjusted operating income $72.4M (‑51% YoY). Reported net loss attributable to common shareholders $411.4M; adjusted net loss $27.2M. Reported diluted EPS (common) ‑$0.47; adjusted diluted EPS ‑$0.03.

Profitability and adjustments

Reported gross margin 61.8% (down ~230 bps YoY); adjusted gross margin also 61.8% (down ~250 bps). Adjusted EBITDA for Q3 was $127.0M (‑38% YoY). Q3 included a $362.8M non‑cash impairment to Consumer Beauty reflecting lower revenue forecasts and a higher WACC; mark‑to‑market on the equity swap reduced results by ~$40.7M in Q3.

Cash flow and balance sheet

Q3 cash used in operations was $203.1M and free cash flow was a $248.7M outflow. However, nine months ended March 31, 2026 cash flow from operations improved to $421.8M and free cash flow to $275.6M. Total debt at quarter end $3,216.2M; financial net debt $2,959.1M and reported net leverage ~3.4x (net debt / adjusted EBITDA).

Segment performance

Prestige: Q3 net revenue $830.9M (flat reported, ‑5% LFL) with adjusted operating income $123.7M. Consumer Beauty: Q3 net revenue $450.7M (‑4% reported, ‑10% LFL) and a reported operating loss driven by the impairment; adjusted operating loss $51.3M.

Regional trends

Americas Q3 revenue $510.4M (‑4% reported, ‑6% LFL) with pressure in U.S./Canada. EMEA $597.6M (‑2% reported, ‑11% LFL) impacted by weaker Middle East sales. Asia Pacific grew to $173.6M (+9% reported, +5% LFL) led by China, Korea and travel retail.

Outlook and guidance

Coty expects Q4 FY26 LFL revenue to decline mid‑single digits (includes a ~2–3% estimated headwind from the Middle East). FY26 adjusted EBITDA guide $838M–$848M and adjusted EPS (ex equity swap) $0.33–$0.35; Q4 adjusted EBITDA expected $85M–$95M with Q4 adjusted EPS (ex equity swap) roughly breakeven to a loss of $0.02. Q4 free cash flow expected to be neutral to moderately positive.

Strategy and corporate actions

Management is implementing the Coty.Curated strategic framework to focus investments, reduce smaller launches, lower marketing asset costs (including expanded AI use), simplify operations and prioritize core brands. The Board added five independent directors, Coty repaid remaining 2026 bond maturities (Apr 15, 2026), and the company highlighted ESG and AI recognitions (MSCI upgrade to AA, SBTi net‑zero validation, Newsweek AI award).

Investor takeaways

Q3 FY2026 shows management beginning to stabilize operations and protect Q4 commercial investments, but results reflect near‑term headwinds (Middle East disruption, tariffs, excess & obsolescence) and a significant non‑cash impairment in Consumer Beauty. Adjusted profitability and FY‑to‑date cash generation provide some offset, while FY27 actions under Coty.Curated aim to improve execution and deleverage over time.

Summarized from source with an LLMView Source

Key figures

-59.9%1Y
-82.7%3Y
-77.5%5Y

Performance

54.2%1Y
42.0%3Y
45.0%5Y

Volatility

Market cap

1726 M

Market cap (USD)

Daily traded volume (Shares)

12,355,290

Daily traded volume (Shares)

1 day high/low

6.99 / 6.81

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.24%USD 20.07
Alkermes PLC
Alkermes PLC Alkermes PLC Valor: 13920929
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.45%USD 43.38
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.44%USD 20.14
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.17%EUR 0.90
Illumina Inc
Illumina Inc Illumina Inc Valor: 1111080
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.68%USD 168.06
Galapagos NV
Galapagos NV Galapagos NV Valor: 2130343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.33%EUR 24.40
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.93%SEK 96.15
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.47%SEK 308.00
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.68%CHF 93.98
Orion Oyj
Orion Oyj Orion Oyj Valor: 2553360
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.60%EUR 70.00